Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Launches TruSight One Sequencing Panel

Published: Tuesday, October 08, 2013
Last Updated: Monday, October 07, 2013
Bookmark and Share
4,800 gene comprehensive panel expands, streamlines, and simplifies sequencing portfolios.

Illumina, Inc. has announced the launch of the TruSight One Sequencing Panel, the industry’s broadest sequencing panel that targets 4,813 genes with known associated clinical phenotypes.

Clinical research laboratories can use this panel to expand existing menus, streamline workflows, or create an entire portfolio of sequencing options, with benefits including increased productivity, reduced handling errors, and decreased costs.

The power of the TruSight One Sequencing Panel is enhanced by Illumina’s user-friendly VariantStudio analysis and reporting software.

To coincide with the introduction of the TruSight One Sequencing Panel, VariantStudio will offer new features that expand annotation and filtering capabilities. These features include support for enabling family-based filtering (mother, father, child, and siblings), providing variant classifications, and generating ready-to-use reports.

In addition, the TruSight One Sequencing Panel can be used to create dozens of “virtual subpanels” to fit the needs of any clinical researcher seeking to understand the genetic basis of disease.

“Illumina is moving in the direction of one simple workflow which will drastically reduce the turnaround time from sample-to-report,” said Matt Posard, Senior Vice President and General Manager of Illumina’s Translational and Consumer Genomics business.

Posard continued, “With the TruSight One Sequencing Panel and enhancements to VariantStudio, Illumina is providing clinical researchers with a simple, cost-effective solution that replaces small sequencing panels with a single robust platform.”

“Our genetics laboratory handles increasing numbers of requests to sequence a wide range of genes believed to be causing inherited disorders,” said Stephen Abbs, Director of Genetics Laboratories, Cambridge University Hospitals NHS Foundation Trust.

Abbs continued, “The broad coverage and high performance of the TruSight One Sequencing Panel allow us to perform these analyses using a streamlined laboratory workflow, as well as to offer a comprehensive, high-quality sequencing service.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Accelerator Welcomes First International Fellow
Illumina Accelerator has expanded their startup pool with the Center of Individualized Diagnostics (CID).
Wednesday, August 24, 2016
Illumina Invests In New Venture Fund
Illumina will commit $100M over 10 years to drive genomic technology development.
Friday, April 15, 2016
Illumina Sues Oxford Nanopore for Patent Infringement
Illumina, Inc. has announced that the company filed lawsuits against Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies, Inc. (ONT).
Wednesday, February 24, 2016
Illumina Signs Multiple Biobank Deals
MEGA array family and next-generation sequencing to support comprehensive genomics approach toward personalized medicine.
Wednesday, February 03, 2016
Illumina Acquires Conexio Genomics
Acquisition strengthens company’s ability to deliver sample-to-report solutions for HLA typing.
Wednesday, January 27, 2016
Illumina Forms New Company
GRAIL to enable early cancer detection via blood-based screening.
Tuesday, January 12, 2016
Bio-Rad, Illumina Partner
Scalable, high-throughput platform to offer unprecedented insight into gene expression of individual cells.
Tuesday, January 12, 2016
Novogene and Illumina Enters into Agreement
Agreement to co-develop NGS diagnostic system for reproductive health and oncology applications.
Wednesday, December 16, 2015
bioMérieux and Illumina Announce the Launch of bioMérieux EpiSeq™
A revolutionary next-generation sequencing service for epidemiological monitoring of bacterial infections.
Tuesday, December 15, 2015
Illumina Accelerator Announces Third Funding Cycle of Genomics Startups
Invests in synthetic biology, reproductive health, skin microbiome and nutrition startups.
Thursday, December 10, 2015
Desktop Genetics Receives Strategic Investment from Illumina
Illumina invests in Desktop Genetics' technology to support the platform's integration with NGS pipelines and improve CRISPR genome editing workflows.
Thursday, December 10, 2015
Amoy Diagnostics and Illumina Enter Strategic Collaboration
Collaboration for next-generation sequencing cancer diagnostics in China.
Thursday, October 01, 2015
Illumina Joins WIN Consortium in Personalized Cancer Medicine
A global network of leading academic, industry, insurance and non-profit research organizations.
Thursday, September 24, 2015
MSK and Illumina Launch Comprehensive Circulating Tumor DNA Program
Collaboration aims to determine range of opportunities for non-invasive cancer diagnosis and monitoring.
Thursday, September 17, 2015
Illumina Completes Acquisition of GenoLogics
Illumina’s to drive the adoption of sequencing in new markets and improve the genomic workflow.
Wednesday, September 02, 2015
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Gene Editing Yields Tomatoes That Ripen Weeks Earlier
Research team develop method to make tomato plants flower and ripen fruit two weeks faster than current growth rates.
Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Unexpected Role for Epigenetic Enzymes in Cancer
Researchers use epigenetics to identify the role of an enzyme family as regulators of genetic message interpretation in yeast.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Genetic Links to Brain Cancer Cell Growth
Researchers discover clues to tumour behaviour from genetic differences between brain cancer cells and normal tissue cells.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!